PM
XBI icon

Prosight Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Prosight Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-273
Closed -$20.8K – 48
2023
Q1 		$20.8K Buy
+273
New +$22.7K 0.01% 41

Other funds holding XBI

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Prosight Management's XBI Position: Q2 2023 in Review

Prosight Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 273 shares — an estimated $20.8K sold.

Prosight Management first reported a position in XBI in Q1 2023 and held it in 1 quarter. The position peaked at $20.8K in Q1 2023. 712 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

  • Prosight Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
  • Prosight Management sold 273 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $20.8K.
  • Prosight Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and held it in 1 quarter.
  • Prosight Management's State Street SPDR S&P Biotech ETF position peaked at $20.8K in Q1 2023.
  • 712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.